A massive "regulatory white space" exists in hematology: after the standard-of-care, azacitidine, fails in higher-risk MDS, 95% of patients have no FDA-approved treatment options and a median survival of less than six months. This makes any drug showing strong efficacy in this setting a potential blockbuster and a critical clinical breakthrough.

Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

For ITP patients with cardiac comorbidities, fostamatinib is a compelling option because it lacks the theoretical thromboembolic risk of TPORAs. Basic science suggests it may even be anti-thrombotic, directly addressing a key safety concern in this high-risk population.

Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.

Concerns about bone marrow fibrosis with TPO receptor agonists have been resolved. The effect is a reversible increase in reticulin fibrosis, not the permanent collagen fibrosis seen in myelofibrosis. It resolves upon stopping the drug, so routine bone marrow biopsies for monitoring are unnecessary.

The next wave of innovation in Essential Thrombocythemia will likely involve combination therapies. Interferons may be paired with novel, highly specific agents targeting driver mutations like CALR and JAK2, moving the field from disease control towards achieving remission or even a cure.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.

While rereading pathology reports is always good practice, it provides the most clinical value in cases of suspected ET. These patients are frequently reclassified as having prefibrotic myelofibrosis, a diagnosis that significantly alters patient counseling, prognosis, and long-term management strategies.

Despite lacking specific FDA approval for chemotherapy-induced thrombocytopenia (CIT), romiplostim is widely used and reimbursed. This is because the influential National Comprehensive Cancer Network (NCCN) endorsed its use based on earlier Phase II data, demonstrating how clinical guidelines can establish standard of care.